CBD News -- Ad Com Thursday for GW Pharma's can
Post# of 75002
Ad Com Thursday for GW Pharma's cannabidiol oral solution for types of epilepsy; shares up 11%
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet on Thursday, April 19, to discuss GW Pharmaceuticals' (GWPH +10.8%) marketing application seeking approval for its cannabidiol oral solution for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients at least two years old.